MEDWIN PUBLISHERS
Committed to Create Value for Researchers

International Journal of Zoology and Animal Biology
ISSN: 2639-216X

Advances in Baculovirus Expression System and its Important Applications

Lisan F[1#], Ullah K[1], Siraj S[1], Akhtar A[3], Lai W[1] and Wang X[1,2*]

[1]Jiangsu Key Laboratory of Sericultural Biology and Biotechnology, School of Biotechnology, Jiangsu University of Science and Technology, China

[2]Key Laboratory of Silkworm and Mulberry Genetic Improvement, Ministry of Agriculture and Rural Affairs, The Sericultural Research Institute, Chinese Academy of Agricultural Sciences, China

[3]Department of Zoology, GC Women University Silakot, Pakistan

Review Article
Volume 7 Issue 6
Received Date: November 01, 2024
Published Date: December 17, 2024
DOI: 10.23880/izab-16000634

***Corresponding author:** Xue-Yang Wang, Associate Professor, School of Biotechnology, Jiangsu University of Science and Technology, Zhenjiang 212100, Jiangsu, China, Email: xueyangwang@just.edu.cn

#Equally contributed towards this aricle.

Abstract

The Baculovirus Expression Vector System (BEVS) inserts foreign genes into insect cells using insect-specific baculoviruses. This strong technique allows high-level recombinant protein expression and correct folding in eukaryotic conditions. For nearly 30 years, it has been a cornerstone of biological research and innovation. This system background and numerous applications are covered in this overview. Baculovirus form, structure, replication mode, and host range are discussed. The ideas and procedures of they are explained, emphasizing its gene delivery efficacy. We study they use in exogenous protein expression, RNA interference, vaccine development, regenerative medicine, and restricted gene therapy in mammalian cells. BEVS plant biotechnology potential is briefly highlighted. It,s biotechnological applications in protein production, biomanufacturing, gene therapy, and vaccine development are also examined. Given system excellent protein expression efficiency, safety for humans and plants, and scalability are objectively compared against its limited host range and laborious initial vector building. The abstract continues with BEVS newest research and future directions, emphasizing its tremendous potential and the need for continuing research to realize it.

Keywords: Baculovirus Expression Vector System; Autographa Californica Multiple Nucleopolyhedrovirus; Application; Adeno-Associate Virus

Introduction

The Concept and Background of the Baculovirus Expression Vector System

The final count emphasizes the relevance of baculovirus expression vector system (BEVS) and its potential usage in defining biotechnology's future. The abstract finishes with a request for given study to unlock its potential. Its rise from a minor aspect of insect biology to a vital part of molecular biology and biotechnology shows its widespread impact on science. This system is uniquely capable of programming the intricate synthesis of many proteins, especially those requiring complex post-translational modifications [1]. This exceptional talent magnetized scientists to a new interesting topic of inquiry. That is opened doors for researchers to study protein structures, crack the codes behind various diseases, and create vital parts for novel vaccines and revolutionary therapeutic interventions [2]. BEVS has had a major impact on biotechnology outside of labs, a testament to adaptability and tenacity. It becomes a crucial tool that helps scientists study gene expression and optimize protein production on a massive scale. These adaptability allows scientists to understand proteins' complex workings, advancing biotechnology [3]. This comprehensive review illuminates BEVS remarkable journey, which began as an intriguing aspect of insect biology and quickly became a vital force that guides molecular studies and propels biotechnology [4]. BEVS is a potent stimulant that accelerates new discoveries and scientific progress in biological research and biotechnology, despite its low-tech methodology. there is more than a scientific breakthrough; it could change biology and offer up new possibilities in biotechnology [5]. Its voyage reflects the continuous spirit of scientific inquiry, leading to innovative discoveries and technologies that will shape biological research and biotechnology applications. It is unveils its numerous dimensions, its history shows the persistence and flexibility of scientific discovery [6]. Its story inspires hope and confirmation of scientific progress and groundbreaking discoveries that are transforming biology and biotechnology into new frontiers [7].

The Wide Applications of Baculovirus in Biological Research and Biotechnology

Baculoviruses are vital for biotechnological and biological research due to their unique properties. It is One of most notable traits is its safety [8]. Since these viruses are insect-specific, they do not harm humans, animals, or the environment. This makes them ideal for safe applications like therapeutic protein production [9]. they have ability to express recombinant proteins makes them popular in biotechnology. they are ideal for large-scale production because they produce lots of proteins. Pharmaceutical manufacture and enzyme creation for various processes are two commercial and research applications that rely on this efficiency [10]. Baculoviruses are necessary for protein folding and post-translational changes, regardless of their expression abilities. Infected insect cells create proteins with correct folding and modifications such glycosylation [11]. Therapeutic proteins often depend on their form and modifications for biological function, making this vital. Baculoviruses help synthesize bioactive proteins that meet biopharmaceutical quality criteria. Baculoviruses' vast insect host range adds to their flexibility [12]. Researchers can choose from many insect hosts to study unique biological processes and insect cell lines. This flexibility helps explain insect cell biology and species differences [13]. Genetic manipulability makes Baculoviruses easier to use in biotechnology and research. Since foreign genes can be easily introduced into the viral genome, researchers can express certain proteins. Tailoring baculovirus-based expression systems to different uses and research goals requires genetic modification [14]. Baculoviruses with insect cell culture make recombinant protein production practical and scalable. This technology is ideal for large-scale industrial production and small-scale research initiatives due to protein expression and cell culture scalability [15]. Besides protein expression, baculoviruses are excellent vaccine candidates. These viruses deliver foreign antigens and boost immunity without harming individuals [16]. To prevent infectious diseases, Baculovirus vaccines are being tested for safety and efficacy. Current gene therapy research emphasizes they have ability to transmit therapeutic genes to desired cells [17]. Their efficient transduction of mammalian cells allows for gene treatments for various genetic diseases. Baculoviruses are versatile biotechnological and biological research tools [17]. Their safety and ability to express proteins with the proper folding and modifications make them crucial for bioactive protein production. Scalability, genetic manipulability, and broad host range increase their flexibility in many research projects. As more is discovered about Baculoviruses, fundamental studies and biotechnology and medicine applications will increase [18].

Basic Features of Baculovirus

The Morphology and Structure of Baculovirus

Baculoviruses are adaptable organisms with biological roles and purposes ingrained in their morphology and structure in biological research and biotechnology. These viruses have rod-shaped virions with diameters of 40–60 nanometers and lengths of 250–300 nanometers [19]. The virus's basic architecture powers its functions and applications. Baculoviruses depend on their nucleocapsid, a helical protein structure that encases and preserves viral DNA [15]. This structure helps transfer genetic material into host cells and protects it during transmission. Nucleocapsids are enveloped by viral lipid bait-layers acquired from host cells during budding. This envelope has several glycoprotein's and spikes, notably the GP64 protein on the Autographa californica multiple nucleopolyhedrovirus (AcMNPV) [20]. these are the major host cell recognition, attachment, and entry interface, starting the infection process. Baculoviruses budding process gives virions their envelopes from changed host cell nuclear membranes. This method creates budded virions, which transmit the infection throughout the host [21]. According to research, certain Baculoviruses produce polyhedra, which are viral protein occlusion bodies. As protective matrices, these polyhedra stabilize the virus and boost insect host oral infectivity. The diverse structural characteristics of baculoviruses could aid biotechnology tremendously [22].

Researchers often use these traits to boost recombinant protein expression. Glycoprotein and viral envelope changes can boost host cell protein synthesis efficiency and target protein yields [23]. Baculoviruses are used as vectors for protein production, emphasizing the need of understanding their morphological and structural characteristics for biotechnology. They have structural research and modification yield biological information and biotechnological advances [24]. Our understanding of these viruses will improve our ability to use them in many scientific pursuits.

The Replication Mode and Host Range of Baculovirus

Baculoviruses mimic superheroes in science and technology. The way they mimic themselves is like a dance with predefined steps. Like a key in a lock, the virus first binds to host cell regions. This attachment is helped by viral proteins like GP64 in AcMNPV. Endocytosis lets the virus enter the host cell after adhering [25]. When the virus envelope unites with the cell membrane, its genetic material enters. Genes flow to the nucleus, the cell's command centre, and behave like a virus's handbook [26]. The cell produces unique proteins when the virus reads its instructions in the nucleus. Without these proteins, the virus cannot replicate. Viruses appear to be building miniature factories within cells [27]. The virus's genetic information must be replicated next. It's like photocopying an important document. This occurs in the nucleus to ensure enough material to make new viruses. The virus develops late genes that make proteins to construct new viral particles as it serves its goal [28]. It seems like builders building something. Late proteins shape new virus particles for cell-to-cell infection. As soon as the infection is ready, leave. Budding releases young viruses from host cells. Like viruses leaving a party. Some Baculoviruses build specialized bodies to protect themselves and infect new hosts [29]. This entire technique is practical and scientifically impressive. Scientists can modify the virus to create medication-related proteins. The virus likes Lepidoptera insects. Like a virus with a hangout spot. It's quite selective, even selecting tissues and cells in developing insects [15]. This pickiness comes from the virus's specific proteins and their interactions with insect cells. Most Baculoviruses are specific to an insect species, but there are differences between kinds [30]. These variants provide an intriguing new dimension to their insect host interactions. Researchers have even found a way to use these viruses as natural insect repellents to control crop pests [12]. In summary, Baculoviruses are exceptional self-replicating organisms that prefer socializing with insects, especially during growth. Scientists employ these viruses to make drugs and protect crops from pests [31]. It works like a super hero virus in science and agriculture!

Principles of the BEVS

The Basic Principles and Mechanisms of the BEVS

BEVS, a complicated molecular tool set, helps scientists make proteins. This approach uses Baculoviruses to transfer protein genetic instructions. After taking over the insect cell, these viruses exploit its machinery to make proteins [32]. Importantly, this method only targets insects and does not harm humans or other living things, making it a safe platform. The baculovirus acts as a molecular puppet master, commanding insect cells to make proteins. The virus's DNA contains the protein's template, neatly wrapped in its delivery vehicle [4]. The virus inserts this genetic material into insect cells, reprogramming the cellular machinery to produce the desired protein. they creates proteins well, making it appealing [1]. Insect cells become highly prolific protein factories when the virus and host cell work together. Because the virus changes the cellular environment, protein production is optimal [16]. The technology is ideal for research and therapeutic protein production due to its high target protein yield. They are aids many scientific sectors. Scientists utilize this technology to manufacture proteins to study biological processes and therapeutic targets [2]. This is helps several scientific fields. Researchers use this technology to make proteins to research biological processes and medicinal targets [9]. It creates proteins that could be used to make vaccines, antibodies, and other biopharmaceuticals. Complex proteins with natural post-translational modifications can be created due to the system's flexibility [33]. Therapeutic protein functioning and safety are essential. They have safety, specifically its insect host specificity, adds assurance in medical applications. They are ideal for biopharmaceutical manufacturing because it reduces contamination and unwanted effects, unlike other expression systems [34]. The BEVS is versatile and used outside of biotechnology. For biopharmaceutical production, they have reduces contamination and unexpected effects compared to conventional expression methods [35]. They are a versatile tool that can be applied beyond traditional biotechnology. It is a potent and adaptable instrument in the molecular scientist's toolbox [36]. One of its main ideas is using Baculoviruses to produce proteins in insect cells. This system leads protein expression technologies due to its efficacy, security, and versatility, advancing science, health, and business [37]. The BEVS continues to profoundly impact biotechnology, whether it is solving cellular function issues or creating life-saving drugs.

The Baculovirus is a Good Gene Delivery Tool

Baculoviruses as gene delivery mechanisms have revolutionized biotechnology and research. The process involves selecting and altering a baculovirus with a gene of interest, usually the versatile and well-behaved AcMNPV [38]. This gene could be altered to produce a therapeutic protein or to study gene functions. When introduced into target cells, the customized baculovirus delivers by accurately finding itself at the designated cellular address [35]. Once inside the cell, the virus delicately releases the foreign gene we seek. The way Baculoviruses integrate foreign genes into cell DNA or store them temporarily is extraordinary [39]. This ensures long-term and consistent gene expression in the host cell, which is necessary for many applications. it can transfer genes to many cell types, making them appealing [40]. Large gene inserts are easily managed and expressed by them. Since they do not multiply in mammalian cells, baculoviruses are safe for gene delivery and diminish viral activity [41]. This gene delivery technology has revolutionized molecular biology by helping scientists comprehend gene function. It,s transfer antigen-coding genes, stimulate a powerful immune response, and help build effective vaccines [42]. they have in gene therapy have exciting futures. it can transfer therapeutic genes into patient cells, making them a promising treatment for many diseases [43]. Current research is aggressively confronting cargo size limits and immune responses, positioning Baculoviruses as vital participants in our quest to understand genetics and open the door to groundbreaking medicines [44]. they are crucial partners in these scientific frontiers, enabling gene function and therapeutic treatment discoveries.

Applications of the BEVS

Research Applications

As a vector for exogenous protein expression: Vectors are used to insert foreign genes into a host organism to express exogenous proteins. This applies to genetic engineering and molecular biology. Plasmid vectors, small, circular DNA molecules that reproduce without the host genome, are often utilized for this type of study [45]. These vectors are carefully designed with all the components needed for successful and regulated protein production. Controlling gene expression requires promoters and enhancers. Enhancers boost gene expression to ensure protein synthesis, while promoters start RNA synthesis from the inserted gene [46]. Selectable markers, usually antibiotic resistance genes, are carefully introduced into vectors to help identify and select cells that have integrated and expressed the vector. Expression system selection is crucial to vector design [47]. Eukaryotic expression vectors are developed for yeast, insect, and mammalian cells, however bacterial expression vectors can express protein in E. coli. The pros and cons of each system affect the protein expression project's success [48]. Vectors can have tags or fusion protein sequences added to their basic design. These extra components aid in protein identification, purification, and experimental techniques [49]. Indubitable systems add complexity to vector design. These systems' promoters allow researchers to precisely control protein expression in response to chemical or environmental inputs. This versatility is useful in experiments that need precise protein production regulation[50]. Vector insertion into host cells, either by transformation for bacteria or transfection for eukaryotic cells, is vital. Chemical transformation, viral transduction, and electro oration are utilized depending on the host organism and experiment [51]. In conclusion, developing vectors for exogenous protein expression is complex and customized, taking into account the experiment's needs, the required level of control, and the host organism's traits. This accuracy ensures target protein production for biotechnology, medicine, and research [52].

As a mediator of RNA interference (RNAi): Vectors enable RNA interference (RNAi), a strong gene expression control method in genetic engineering and molecular biology. Small RNA molecules like shRNA or siRNA are used in RNA interference (RNAi) to target and reduce gene expression [53]. Vectors designed for RNA interference (RNAi) carry small RNA molecules into target cells. Vectors are key to this procedure. Plasmid vectors are among the many vectors used for this. These vectors can express short RNA sequences that carry siRNA/shRNA molecules directly or resemble natural microRNAs. Because plasmid vectors are so variable, researchers may tailor the RNAi approach to their findings, making gene silencing studies flexible [54]. Upon insertion into host cells, these small RNA molecules coordinate the RNA-induced silencing complex (RISC). The RISC complex uses small RNA molecules to precisely find the silenced gene's target mRNA. Translational repression or degradation of the targeted mRNA reduces gene expression precisely and regulated [55]. RNA interference (RNAi) employs vectors to distribute small RNA molecules correctly and achieve long-term silencing. Vectors enable several RNA interference (RNAi) applications. These vectors selectively silence genes, allowing functional genomics researchers to fully study gene functions [56]. RNAi vectors can also be used to develop therapies for a variety of hereditary conditions by altering gene expression. Designing and optimizing vectors for RNA interference requires careful consideration of several criteria. This includes target gene features, cell type distribution effectiveness, and experimental setup demands [57]. Researchers are continually developing and designing novel RNAi vector designs to boost specificity, reduce off-target effects, and extend biological and medical research applications. Overall, vectors and RNA interference technologies are a sophisticated way to understand gene function and have great potential for therapeutic interventions in the ever-changing field of molecular biology [58].

As a vaccine carrier: Vectors are vital for antigen transport and vaccine production in biotechnology and vaccination. A vaccine vector transports and expresses antigenic proteins or genetic material into the host organism [59]. This causes an immunological reaction that produces antibodies and a pathogen-specific immune memory. Virus vectors are used to make vaccinations. Antigen-encoding viral vectors carry and disseminate pathogen genetic material. Often, these vectors are made non-pathogenic [60]. These vectors infect and express antigen in host cells. T cells and antibodies are activated when the immune system recognizes the generated antigen as alien. This immune reaction protects against the infection later. Besides viral vectors, bacterial and other non-viral vectors are being investigated for vaccine production [61]. These vectors may contain DNA or proteins encoding antigens, which activate immune mechanisms. Pathogen features, immunological response, and safety all affect vector selection. Vaccination vectors are versatile beyond antigen transport. Certain vectors contain adjuvants that boost vaccination immunity. Adjuvant-containing vaccines often have increased efficacy and a stronger, longer-lasting immune response [62]. Using vectors in vaccine production allows for new immunization methods. RNA-based vectors, like mRNA vaccines, are popular because they can command cells to temporarily produce viral antigens, emulating a natural infection without producing sickness. Modern vaccinations against various viruses have been successful using this inventive approach [63]. Overall, vector-based vaccine delivery is an attractive and cutting-edge biotechnology topic. Vector design and selection are crucial to developing safe and effective vaccines that fight infectious illnesses and advance immunology. Integration of diverse vector platforms continues to improve global public health and vaccine creation as technology advances [64].

For regenerative medicine: Vectors can deliver therapeutic genes to cells and tissues, regenerating harmed or sick organs. Vectors, often viruses or non-viruses, carry and introduce genetic material into patient cells. Tissue regeneration, cellular repair, or cell replacement are the goals [65]. Regenerative medicine uses viral vectors for safe and effective delivery. Modified viruses like AAVs and lentiviruses can insert therapeutic genes into target cells without infecting them. Once within cells, these vectors trigger gene expression for tissue regeneration and repair proteins [66]. Their genes may promote angiogenesis, stem cell differentiation into specific cell types, or cell proliferation. Non-viral vectors like liposomes, nanoparticles, and others may be promising in regenerative medicine. Encapsulating and shielding therapeutic genes in vectors makes gene transfer easier into target cells [67]. Despite being safer and easier to make, scientists are continually improving non-viral vector specificity and efficiency. Regenerative medicine tackles congenital abnormalities, degenerative diseases, and traumas with vectors. Vector-based gene therapy can regenerate the heart after myocardial infarction, restore neuronal function in neurodegenerative illnesses, and repair injured musculoskeletal tissues [68]. New regenerative medicine methods use vectors to control and improve endogenous cell regeneration. These vectors may carry genes that activate signalling pathways, mobilize stem cells, or change the local milieu to facilitate tissue healing. Vector design and optimization for regenerative medical applications must include target tissue, delivery efficacy, and safety [69]. Researchers are exploring new vector technologies and delivery methods to overcome hurdles and realize the full potential of regenerative therapies [70]. Finally, vectors are crucial to regenerative medicine, paving the way for innovative medicines that actively repair and regenerate wounded tissues rather than just masking symptoms. Regenerative medicine is an exciting and rapidly evolving discipline that benefits from novel vector-based approaches [71].

As a means of gene therapy in mammalian cells: Vectors are crucial delivery vehicles for therapeutic genes in mammalian cell-specific gene therapy, a cutting-edge method for correcting or replacing mistranslated genetic material in inherited diseases. Gene therapy is a revolutionary method for correcting molecular defects connected to illnesses by inserting genetic material into cells [72]. Vectors are crucial to this therapeutic effort because they accurately transport therapeutic genes to affected cells. Most vectors employed in mammalian cell gene therapy are viruses, especially lentiviruses and AAVs [73]. These vectors have been carefully engineered to be safe and effective carriers that can remain episomal DNA or integrate therapeutic genes into the host cell's genome. Their altered forms can infect many cell types, making them ideal for treating genetic diseases. Liposomes, nanoparticles, and synthetic carriers complement viral vectors and play a vital role in gene therapy. Safer, less immunogenic, and more efficient manufacturing are benefits of these vectors. Non-viral vectors may not be as successful in integrating genes into the host genome as viral vectors, although they are being improved via research and development [74]. The therapeutic genes vectors introduce into cells are the foundation of gene therapy. These genes are carefully designed to replace or fix the disease-causing genes. Gene therapy delivers a functioning gene copy into the patient's cells for monogenic diseases with a single defective or absent gene. Therapeutic genes can do more than replace missing genes, boosting gene therapy's therapeutic potential [75]. They can also be designed to boost immunological responses, alter cellular activities, or induce therapeutic protein production. Gene therapy relies on vector engineering and optimization. Vector tropism affects cell type targeting, cellular milieu durability, and immune response. As crucial is the delivery mechanism's continual and controlled synthesis of therapeutic genes for long-term benefits. Vector-driven gene therapy has shown promise in treating inherited disorders, malignancies, and immune system deregulation [76]. Since vector design research develops, gene therapy could revolutionize genetic ailment treatment and personalized medicine. This intersection of molecular precision and therapeutic innovation highlights vectors' critical role in directing gene therapy towards a future where hereditary disorders are not only treated but also repaired at their genetic bases [77].

As an expression vector in plants: In the ever-changing field of plant biotechnology, vectors are crucial for correct genome alteration and foreign gene uptake and expression in plant cells. Known as "expression vectors," these advanced vectors have revolutionized plant genetic engineering and enabled crop improvement, GMO creation, and bio-based product production [78]. Agrobacterium tumefaciens is a frequent vector for plant genetic engineering. Because of its smart design, this soil bacteria's Ti plasmid can transfer foreign genes. The necessary genes are introduced into Agrobacterium, which infects plant cells, to gradually integrate them into the plant genome. This natural and widely beneficial method is necessary to create transgenic plants with altered characteristics or abilities [79]. In addition to Agrobacterium-based vectors, particle bombardment and viral vectors can transport genes to plant cells. Plant virus-derived viral vectors that transfer foreign genes leverage viruses' natural tendency to infect plants. Particle bombardment, which involves physically inserting DNA-coated particles into plant cells, is more direct and versatile [80]. These methods offer flexibility for target plant species and genetic alteration requirements. Expression vectors transmit genes into plants for industrial, medical, and agricultural uses. These vectors help create genetically altered crops with improved nutrition, stress tolerance, and pest resistance [81]. Expression vectors help genetic engineers create plant tissue proteins, enzymes, and metabolites. Another trend in biopharmaceuticals is the use of plant-based expression systems to synthesize therapeutic proteins and other biomedical drugs at a lower cost. During plant expression vector design, numerous parameters must be considered to ensure maximal performance [82]. For imported gene expression, researchers introduce enhancers, terminators, and promoters into vectors to control timing and level. Selectable indicators, such as antibiotic-resistant genes, assist in identifying and selecting transformed plants, speeding up genetically altered crop creation [83]. In conclusion, vectors as expression vectors in plants allow scientists to completely exploit genetic modification for a variety of functions in modern plant biotechnology. These vectors enable creative and sustainable bio-based product manufacture while solving agricultural problems. Technology and vector design and delivery techniques are improving, making plant genome alteration for industry, agriculture, and medicine increasingly promising [51].

Biotechnological Applications

The application of the BEVS in protein expression and bio-manufacturing: The BEVS, a versatile platform that has revolutionized recombinant protein synthesis, is vital to protein expression and biomanufacturing. Its unique capacity to express target proteins at high levels makes it important [33]. Scientists can precisely build Baculoviruses to express and carry certain genes, allowing them to govern target protein synthesis in mammalian and insect cells. They have unique capacity to enable post-translational modifications is critical for synthesis of biologically relevant proteins. By mimicking mammalian cell changes, this characteristic ensures that recombinant proteins keep their original shape and function [84]. This affects the synthesis of membrane and multi-subunit proteins, making the system versatile for many protein types and applications. Safety is paramount in biomanufacturing, especially when making therapeutic proteins [11]. Because of its limited ability to reproduce in mammalian cells, the BEVS protects protein expression from viral activity. This safety feature makes it more appealing for applications with strict regulatory requirements [85]. BEVS's genetic editing capabilities lets scientists readily change virus genomes, another unique feature. It can optimize protein manufacturing methods and manufacture specific proteins in tests because it is so easy to use [86]. The technology can be scalable for large-scale industrial biomanufacturing and small-scale laboratory studies. Scalability allows it to adapt to research and commercial production needs, contributing to its appeal [87]. Its cost-effectiveness makes BEVS protein manufacturing economically viable. This saves resources without compromising protein expression, which benefits research institutes and biomanufacturing companies [88]. The BEVS is widely used in biopharmaceutical manufacturing. Superior proteins like monoclonal antibodies, viral antigens, and vaccines have advanced medical research [89]. Decades of research have led to strong techniques and methods that streamline the protein expression process and ensure its reliability in a variety of biomanufacturing situations [9]. BEVS is essential and multifunctional in protein-based research and biomanufacturing. Its high-level expression, post-translational modifications, adaptability, safety, simplicity of manipulation, scalability, affordability, and specific uses in biopharmaceutical manufacturing demonstrate its critical role in modern biotechnology [90]. As the market for recombinant proteins increases, the baculovirus expression technology continues to pioneer research into biopharmaceuticals.

The potential of the BEVS in gene therapy and vaccine development: Due to its protein production flexibility, the BEVS has shown considerable promise as a platform for gene therapy and vaccine research, presenting significant potential for additional improvements in both fields [84].

The method can transport genes into a variety of host cells in vitro and in vivo, making it ideal for gene therapy. Baculoviruses like AcMNPV can carry therapeutic genes to target specific tissues or organs [38]. The approach is suitable for gene therapy since it is safe in mammalian cells and can express injected genes at high levels. Baculovirus expression has been successful in creating viral antigens for subunit vaccines. By adding antigen-encoding genes into the baculovirus genome, scientists can construct recombinant viruses that express certain host cell antigens [91]. This approach makes immunogenic, well-folded viral proteins easier to manufacture, replicating genuine infections. Complex proteins, particularly membrane proteins, are often required in vaccines, and the system can express them [18]. This method simplifies immunogenic, well-folded viral protein production, propagating infections. The system can express complex proteins, especially membrane proteins, needed in vaccinations [92]. Baculovirus-produced vector-lent polymers (VLPs) are effective vaccine candidates that boost immunity. The system can express vector-like proteins (VLPs) for influenza and human papillomavirus, demonstrating its vaccine production versatility [93]. it,s safety in mammalian cells is important for creating vaccines and gene therapy. Baculoviruses proliferate poorly in mammalian cells, reducing the risk of undesired viral activity. This safety feature makes the system more appealing for Biosafety-sensitive applications like vaccine and gene therapy delivery [94]. While immunological reactions to baculovirus vectors and the need for appropriate targeting in gene therapy remain challenges, genetic engineering research is addressing these [1,5]. it can affect gene therapy and vaccine development due to their safety, efficacy, and adaptability. The BEVS shows promise in vaccine and gene therapy development, showing its potential to advance these therapies [95]. For applications demanding accuracy, dependability, and robust immune responses, its versatility, safety, and ability to express complex proteins make it a good choice. As these fields of inquiry evolve, this is expected to drive discoveries and breakthroughs that could treat and prevent many diseases [42,96].

Advantages and Disadvantages of the BEVS

Advantages of the BEVS

The Baculovirus Expression Vector System (BEVS) is a leading protein expression system that meets biotechnology and biological research needs. One of its biggest advantages is its unequalled protein expression. Basic laboratory research and large-scale protein manufacturing that require large-scale recombinant protein production benefit from this capability [18]. it have ability to accurately imitate post-translational modifications such glycosylation patterns in human cells ensures protein folding and biological activity. Basic laboratory research and large-scale protein manufacturing that require large-scale recombinant protein production benefit from this capability [97]. Bio-pharmaceuticals and other protein-based treatments require this feature for functionality. It is also allows the production of eukaryotic proteins in conditions similar to their cellular milieu. Since improper folding can affect a protein's biological activity, this component is crucial for appropriate protein structure and function [98]. The system's flexibility allows the production of complex membrane proteins and multi-subunit complexes. BEVS solves problems with other expression systems, making it the preferred method for researchers working with many protein targets. it is scalable, making it suitable for large-scale biomanufacturing. This makes protein production scale smoothly to meet industrial needs [99]. they have safety is improved by using insect-specific baculoviruses, which do not multiply in human cells and protect laboratory workers. The approach also lets researchers choose promoters and expression mechanisms to customize protein expression levels. Baculoviruses huge genomes and sophisticated transfer vectors make it,s easy to manipulate [100]. These traits enable accurate cloning and modification of foreign genes in the viral genome and the easy insertion of large or numerous target genes. they has been a reliable and crucial resource in the biotechnology and pharmaceutical industries for decades, advancing scientific and protein manufacturing developments. Its constant growth and adaptability to new technologies ensure its importance in molecular biology and biotechnology [101].

Disadvantages of BEVS

The Baculovirus Expression Vector System (BEVS) has revolutionized protein expression in industrial and research settings due to its many benefits. Like every technology, BEVS has limitations, which must be acknowledged to properly utilize it and overcome hurdles. It is One of downsides is recombinant baculovirus creation's complexity [97]. This process involves complex steps like creating a transfer vector with the desired gene, co-transfecting it into insect cells with wild-type baculovirus DNA, and isolating and characterizing recombinant baculovirus clones. Each of these processes requires careful preparation, significant technical expertise, and optimization, which takes time and effort. Size limits on baculovirus vector-inserted genes limit BEVS [99]. Despite having greater capacity than other viral vectors, baculovirus vectors have inherent constraints on DNA fragment size. This constraint can make it difficult to express multiple genes in a single construct, especially with baculovirus strains with restricted packaging capabilities. Another problem of BEVS is that insect and human cells glycosylation differently [98]. Despite similarities, insect and mammalian cells glycosylation proteins differently. This discrepancy may affect glycosylated proteins' biological activity and functionality, especially those that require specific glycosylation patterns for folding and activity. When using BEVS to express proteins, researchers must consider their target proteins' glycosylation demands. Hazardous proteins in insect cells may also affect BEVS-based protein synthesis [102]. Certain proteins may naturally poison insect cells, reducing or killing them. This toxicity can make protein expression harder and reduce recombinant protein production. Researchers may need to try new protein production methods or enhance expression settings to circumvent this constraint. Some mammalian post-translational modifications may not be properly duplicated in insect cells [103]. Insect cells can perform some post-translational modifications, however they may not match mammalian cells' range. Insect cells can perform some post-translational modifications, however they may not match mammalian cells' range. This restriction may influence protein activity and function, especially those that need specific alterations. Scientists must carefully evaluate it for their protein expression needs, taking into account their target proteins' post-translational modification requirements[104]. they has many practical and technological issues that may limit its utility and scalability. Large-scale protein production may be financially expensive due to it higher production costs than bacterial expression systems like Escherichia coli [8]. Serum-free medium and insect cell manufacturing may increase prices. Baculovirus-infected insect cells take longer to express proteins, which may slow protein production for time-sensitive applications. they may have less uses due to the lack of well-characterized and high-performing insect cell lines compared to mammalian cell lines [92]. they often use insect cell lines like Trichoplusia ni (High Five) and Spodoptera frugiperda (Sf9), but their performance can vary, so researchers may need to spend more time and money fine-tuning expression conditions. Because insect-specific glycosylation patterns and biocontainment concerns from baculovirus infections may cause human immunogenicity, strict safety and risk evaluation processes are needed [105]. Since baculoviruses cannot multiply in mammalian cells and are safe for laboratory use, they must be carefully managed to avoid inadvertent release into the environment or human exposure. They provides several advantages for protein expression and biotechnology, but its shortcomings must be understood and addressed [106]. Investigators can optimize BEVS's effectiveness and security for their scientific and commercial needs by understanding these limitations and applying appropriate ways to mitigate them. it is a useful biotechnology technique because it offers unprecedented versatility and variety for protein production and expression, despite its drawbacks [107].

Latest Research and Future Developments

Studies and design of the Baculovirus Expression Vector System (BEVS) have advanced in recent years to optimize its benefits and resolve its drawbacks. Its ability to produce huge amounts of protein in insect cells has made BEVS a powerful recombinant protein producer [18]. However, scientists are also working to overcome it,s challenges such vector production, protein expression limits, and mammalian glycosylation patterns. These activities have led to groundbreaking discoveries in molecular biology and biotechnology that augur well for BEVS [97]. Increasing vector construction efficiency is a BEVS research priority. Researchers have explored innovative cloning strategies to generate recombinant baculoviruses faster than traditional vector creation methods. These improvements should make vector construction easier and more successful for researchers in several domains [99]. Cutting-edge modular assembly and synthetic biology methods help researchers design and build it vectors more easily and precisely. This allows faster and more reliable recombinant baculovirus manufacturing. To optimize protein expression, they has been heavily used. Drug discovery, vaccine development, and structural biology require high protein expression levels [104]. Researchers altered insect cell post-translational events to increase protein folding and function. Promoter engineering, signal peptide engineering, and codon optimization boost BEVS protein expression. By altering these factors, researchers hope to boost and stabilize recombinant protein output, making BEVS more versatile [107].

Novel baculovirus strains or variants can advance it,s research. Baculoviruses have thousands of genetic strains. Researchers strive to find strains with better host ranges, infection efficiency, and other features. Scientists intend to develop vector systems with improved performance and adaptability using baculovirus genetic variation [105]. Gene therapy and vaccine research require certain vector qualities, making these projects vital. Current BEVS research focuses on insect cell glycosylation patterns. Glycosylation is crucial to protein folding, stability, and function, especially therapeutic proteins [108]. However, insect cells produce glycoprotein's with different glycosylation patterns than mammalian cells, which may impact recombinant protein immunogenicity and biological function. Genetic engineering in insect cells to create glycosylation patterns like those in mammalian cells is being studied to solve this problem [109]. This research aims to improve BEVS-made recombinant proteins' therapeutic potential by altering insect cells to have mammalian glycosylation patterns. Bioprocessing technologies that emphasize scalability and affordability are also influencing BEVS research [110]. Industrial-scale BEVS recombinant protein manufacture requires efficient bioprocessing to maximize productivity and reduce costs. Researchers are studying downstream processing methods including integrated process design and continuous purification to improve process efficiency and production workflow. Advanced bioreactor systems and culture environment optimization are being used to increase BEVS cell growth and protein expression kinetics [95]. they have full potential in industrial settings, where large-scale, effective protein production is essential, depends on these improvements. More research is being done on it vaccine potential. BEVS has various vaccine manufacturing advantages, including the ability to express complex antigens with correct folding and post-translational modifications [98]. We need vaccines to prevent and control infectious diseases. Researchers are using the system's viral antigen production to develop next-generation vaccines against bacteria, viruses, and parasites. Researchers intend to improve immunization by using BEVS to express vaccine antigens and create more scalable, adaptive, and effective vaccines [111]. it has a promising future in molecular biology and biotechnology due to its invention and application possibilities. Integrating synthetic biology and CRISPR/Cas systems improves system efficiency [112]. This offers enormous opportunity to improve it,s protein expression and applicability. The ability to accurately change baculovirus genomes allows the system to be customized to fit specific expression needs, increasing its flexibility and adaptability. As BEVS evolves, academic-industry partnerships will develop [113].

Conclusion and Prospect

The Importance and Application Prospects of the BEVS

Protein production applications depend on the Baculovirus Expression Vector System (BEVS), a molecular biology and industrial staple. Its versatility and efficiency make it crucial for manufacturing proteins, especially membrane proteins, which are complex. it is widely used in pharmaceutical research and biopharmaceutical production. The approach can produce large volumes of appropriately folded and functioning therapeutic proteins, especially those requiring complex post-translational modifications. Continued progress supports BEVS's promise. Researchers are improving the system's scalability, making it suitable for large-scale protein manufacturing. Scaling is especially important in biotechnology, where protein expression platforms must be successful and inexpensive. Additionally, they are major vaccine developer. The system's ability to express viral antigens makes it a versatile platform for developing infectious disease vaccines. This application shows how it can adapt to new challenges to produce preventative healthcare solutions. It,s importance in molecular biology and biotechnology cannot be overstated. The vast range of protein expression capabilities, continual scalability improvements, and expanding importance in vaccine development make it a vital research and industry tool. As innovations progress, BEVS will likely become more essential in protein expression and biopharmaceutical manufacturing.

Emphasize the Importance of Further Researching this System

The Baculovirus Expression Vector System (BEVS) is a molecular biology and biotechnology staple that excels in drug discovery, protein expression, and biopharmaceutical manufacture. Its ability to efficiently express complex proteins, particularly membrane proteins, has benefited research and industry. it has proven its worth, but more research is needed. Continued research can improve it,s capabilities, fixing problems and offering new research avenues. Scalability is important in industrial applications and ensures simple integration into large-scale protein manufacturing facilities. BEVS is a potential vaccine development candidate, therefore more research may lead to optimized vaccines for more infectious diseases. New baculovirus strains, vector assembly methods, and bioprocessing methods can lead to groundbreaking discoveries. In conclusion, it,s importance in biotechnology and molecular biology suggests revolutionary results from further research. Research and development in this field is crucial to increasing it application scalability, adaptability, and efficiency. This could advance protein expression and biopharmaceutical development. Further BEVS research is needed to promote the scientific and industrial development of this essential tool.

Prospect

The Baculovirus Expression Vector System (BEVS) has a bright future due to ongoing and possible innovations. Research intends to expand it for large-scale protein production and improve bioprocessing processes for productivity. Researching and producing novel baculovirus strains can improve infection and host ranges. The capacity to engineer insect cells to create human-like glycosylation patterns is crucial for biopharmaceutical production. It,s participation in vaccine development is projected to rise, indicating its versatility in developing infectious disease vaccines. Through integration with new technologies, expression vector customization, and novel biotechnology, BEVS may shape protein expression and biotechnology. These variables boost the company's potential.

Reference

1. Van Oers MM (2011) Opportunities and challenges for the baculovirus expression system. Journal of invertebrate pathology 107: S3-S15.

2. O'Reilly DR, Miller LK, Luckow VA (1994) Baculovirus expression vectors: a laboratory manual. Oxford University Press.

3. Kusakabe T (2023) Production of antiviral vaccine

antigens using a silkworm-baculovirus expression system. Journal of Pharmacological Sciences 151(3): 156-161.

4. Palomares LA, Estrada-Mondaca S, Rami OT (2005) Principles and applications of the insect cell-baculovirus expression vector system, in Cell culture technology for pharmaceutical and cell-based therapies CRC Press pp: 645-710.
5. Liu F (2013) Use of baculovirus expression system for generation of virus-like particles: successes and challenges. Protein expression and purification 90(2): 104-116.
6. Hitchman RB, Possee RD, King LA (2009) Baculovirus expression systems for recombinant protein production in insect cells. Recent patents on biotechnology 3(1): 46-54.
7. Richardson CD (2008) Baculovirus expression protocols. Springer Science & Business Media 39.
8. Tsai CH (2019) Baculovirus as versatile vectors for protein display and biotechnological applications. Current issues in molecular biology 34(1): 231-256.
9. Kost TA, Condreay JP, Jarvis DL (2005) Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nature biotechnology 23(5): 567-575.
10. Grzywacz D (2017) Basic and applied research: Baculovirus, in Microbial control of insect and mite pests. Elsevier pp: 27-46.
11. Kost TA, Kemp CW (2016) Fundamentals of baculovirus expression and applications. Advanced technologies for protein complex production and characterization pp: 187-197.
12. Blissard GW, Rohrmann GF (1990) Baculovirus diversity and molecular biology. Annual review of entomology 35(1): 127-155.
13. Van Oers MM, Pijlman GP, Vlak JM (2015) Thirty years of baculovirus–insect cell protein expression: from dark horse to mainstream technology. Journal of General Virology 96(1): 6-23.
14. Maeda S (2018) Expression of foreign genes in insect cells using baculovirus vectors. Insect cell biotechnology pp: 1-42.
15. Rohrmann GF (2019) The baculovirus replication cycle: Effects on cells and insects. Baculovirus molecular biology.
16. Jarvis DL (2009) Baculovirus–insect cell expression systems. Methods in enzymology 463: 191-222.
17. Moscardi F (2011) Baculovirus pesticides: present state and future perspectives, in Microbes and microbial technology: Agricultural and environmental applications. Springer pp: 415-445.
18. Possee RD (2019) Recent developments in the use of baculovirus expression vectors. Current Issues in Molecular Biology 34(1): 215-230.
19. Wang Q (2016) Budded baculovirus particle structure revisited. Journal of invertebrate pathology 134: 15-22.
20. Sajjan DB, Hinchigeri SB (2016) Structural organization of baculovirus occlusion bodies and protective role of multilayered polyhedron envelope protein. Food and environmental virology 8: 86-100.
21. Coulibaly F (2009) The atomic structure of baculovirus polyhedra reveals the independent emergence of infectious crystals in DNA and RNA viruses. Proceedings of the National Academy of Sciences 106(52): 22205-22210.
22. Kelly BJ, King LA, Possee RD (2016) Introduction to baculovirus molecular biology. Baculovirus and Insect Cell Expression Protocols pp: 25-50.
23. Kelly BJ, King LA, Possee RD (2007) Introduction to baculovirus molecular biology. Baculovirus and insect cell expression protocols pp: 25-53.
24. Herniou EA, Jehle JA (2007) Baculovirus phylogeny and evolution. Current drug targets 8(10): 1043-1050.
25. Kool M (1995) Replication of baculovirus DNA. Journal of General Virology 76(9): 2103-2118.
26. Rohrmann GF (2019) The baculovirus replication cycle: Effects on cells and insects, in Baculovirus Molecular Biology. In: 4th (Edn.), National Center for Biotechnology Information, USA.
27. Kelly D (1982) Baculovirus replication. Journal of General Virology 63(1): 1-13.
28. Wu C (2016) Generating a host range-expanded recombinant baculovirus. Scientific reports 6(1): 28072.
29. Granados RR (1980) Infectivity and mode of action of baculoviruses. Biotechnology and Bioengineering 22(7): 1377-1405.
30. Hefferon KL (2004) Baculovirus late expression factors. Microbial Physiology 7(3): 89-101.

31. LaCount DJ (1998) Virus replication events and host factors involved in baculovirus-induced apoptosis. The University of Wisconsin-Madison.

32. King L (2012) The baculovirus expression system: a laboratory guide. Springer Science & Business Media.

33. Contreras-Gómez A (2014) Protein production using the baculovirus-insect cell expression system. Biotechnology progress 30(1): 1-18.

34. HU YC (2005) Baculovirus as a highly efficient expression vector in insect and mammalian cells. Acta Pharmacologica Sinica 26(4): 405-416.

35. Hüser A, HofmannC (2003) Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications. American Journal of Pharmacogenomics 3: 53-63.

36. Luckow VA, Summers MD (1988) Trends in the development of baculovirus expression vectors. Bio/ technology 6(1): 47-55.

37. Sokolenko S (2012) Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and drawbacks. Biotechnology advances 30(3): 766-781.

38. Ono C (2018) Baculovirus as a tool for gene delivery and gene therapy. Viruses 10(9): 510.

39. Mansouri M, Berger P (2018) Baculovirus for gene delivery to mammalian cells: Past, present and future. Plasmid 98: 1-7.

40. Hu YC (2008) Baculoviral vectors for gene delivery: a review. Current gene therapy 8(1): 54-65.

41. Kost TA, Condreay JP (2002) Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends in biotechnology 20(4): 173-180.

42. Chen CY (2011) Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications. Biotechnology advances 29(6): 618-631.

43. Räty JK (2004) Enhanced gene delivery by avidin-displaying baculovirus. Molecular therapy 9(2): 282-291.

44. Tani H (2003) In vitro and in vivo gene delivery by recombinant baculoviruses. Journal of Virology 77(18): 9799-9808.

45. Shi N (2001) Brain-specific expression of an exogenous gene after iv administration. Proceedings of the National Academy of Sciences 98(22): 12754-12759.

46. Wang H (2015) Using rabies virus vaccine strain SRV9 as viral vector to express exogenous gene. Virus genes 50: 299-302.

47. Yen L (2004) Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature 431(7007): 471-476.

48. Jacobs A (2001) Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. The Lancet 358(9283): 727-729.

49. Betti F (2021) Exogenous miRNAs induce post-transcriptional gene silencing in plants. Nature Plants 7(10): 1379-1388.

50. Ye C (2019) Induction of RNAi core machinery's gene expression by exogenous dsRNA and the effects of pre-exposure to dsRNA on the gene silencing efficiency in the pea aphid (*Acyrthosiphon pisum*). Frontiers in Physiology 9: 419-515.

51. Burnett MJ, Burnett AC (2020) Therapeutic recombinant protein production in plants: Challenges and opportunities. Plants, People Planet 2(2): 121-132.

52. Wu CP (2021) The influence of serial passage on the stability of an exogenous gene expression in recombinant baculovirus. Entomological Research 51(4): 168-175.

53. Hung YH, Slotki RK (2021) The initiation of RNA interference (RNAi) in plants. Current Opinion in Plant Biology 61: 102014.

54. Xu W, Jiang X, Huang L (2019) RNA interference technology. Comprehensive biotechnology pp: 560.

55. Cooper AM (2019) Molecular mechanisms influencing efficiency of RNA interference in insects. Pest management science 75(1): 18-28.

56. Zhu KY, Palli SR (2020) Mechanisms, applications, and challenges of insect RNA interference. Annu Rev Entomol 65: 293-311.

57. Sioud M (2021) RNA interference: story and mechanisms. Design and Delivery of SiRNA Therapeutics pp: 1-15.

58. Bartoszewski R, Sikorski AF (2019) Editorial focus: understanding off-target effects as the key to successful RNAi therapy. Cellular & molecular biology letters 24: 1-23.

59. Cao W (2020) Recent progress of graphene oxide as a

potential vaccine carrier and adjuvant. Acta biomaterialia 112: 14-28.

60. Jazayeri SD (2021) Nano and microparticles as potential oral vaccine carriers and adjuvants against infectious diseases. Frontiers in pharmacology 12: 682286.

61. Marini A (2019) A universal plug-and-display vaccine carrier based on HBsAg VLP to maximize effective antibody response. Frontiers in immunology 10: 500416.

62. Franck CO (2021) Biopolymer-based carriers for DNA vaccine design. Angewandte Chemie International Edition 60(24): 13225-13243.

63. Lang S, Huang X (2020) Carbohydrate conjugates in vaccine developments. Frontiers in Chemistry 8: 284.

64. Zeng L (2020) Non-covalent glycosylated gold nanoparticles/peptides nanovaccine as potential cancer vaccines. Chinese Chemical Letters 31(5): 1162-1164.

65. Rajabzadeh N, Fathi E, Farahzadi R (2019) Stem cell-based regenerative medicine. Stem cell investigation 6: 19.

66. Han Y (2019) Mesenchymal stem cells for regenerative medicine. Cells 8(8): 886.

67. Ren X (2020) Growth factor engineering strategies for regenerative medicine applications. Frontiers in bioengineering and biotechnology 7: 469.

68. Catoira MC (2019) Overview of natural hydrogels for regenerative medicine applications. Journal of Materials Science: Materials in Medicine 30: 1-10.

69. Pina S (2019) Scaffolding strategies for tissue engineering and regenerative medicine applications. Materials 12(11): 1824.

70. Mas-Bargues C (2019) Relevance of oxygen concentration in stem cell culture for regenerative medicine. International Journal of Molecular Sciences 20(5): 1195.

71. Fathi-Achachelouei M (2019) Use of nanoparticles in tissue engineering and regenerative medicine. Frontiers in bioengineering and biotechnology 7: 113.

72. Ma CC (2020) The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology advances 40: 107502.

73. Bulaklak K, Gersbach CA (2020) The once and future gene therapy. Nature communications 11(1): 1-4.

74. Wang D, Tai PW, Gao G (2019) Adeno-associated virus vector as a platform for gene therapy delivery. Nature reviews Drug discovery 18(5): 358-378.

75. Bulcha JT (2021) Viral vector platforms within the gene therapy landscape. Signal transduction and targeted therapy 6(1): 53.

76. Uddin F, Rudin CM, Sen T (2020) CRISPR gene therapy: applications, limitations, and implications for the future. Frontiers in oncology 10: 1387.

77. Shahryari A (2019) Development and clinical translation of approved gene therapy products for genetic disorders. Frontiers in genetics 10: 450496.

78. Gao Q (2019) Rescue of a plant cytorhabdovirus as versatile expression platforms for planthopper and cereal genomic studies. New Phytologist 223(4): 2120-2133.

79. Jiang N (2019) Development of Beet necrotic yellow vein virus-based vectors for multiple-gene expression and guide RNA delivery in plant genome editing. Plant biotechnology journal 17(7): 1302-1315.

80. Peyret H, Brown JK, Lomonossoff GP (2019) Improving plant transient expression through the rational design of synthetic 5′ and 3′ untranslated regions. Plant methods 15: 1-13.

81. Abrahamian P, Hammond RW, Hammond J (2020) Plant virus–derived vectors: Applications in agricultural and medical biotechnology. Annual Review of Virology 7: 513-535.

82. Rybicki EP (2020) Plant molecular farming of virus-like nanoparticles as vaccines and reagents. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 12(2): e1587.

83. Cody WB, Scholthof HB (2019) Plant virus vectors 3.0: transitioning into synthetic genomics. Annual review of Phytopathology 57: 211-230.

84. Felberbaum RS (2015) The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnology journal 10(5): 702-714.

85. Kretzdorn D (2003) Protein expression in baculovirus vector expression systems. Google Patents.

86. Marek M, van Oers MM, Devaraj FF, Vlak JM, Merten OW (2011) Engineering of baculovirus vectors for the manufacture of virion-free biopharmaceuticals. Biotechnology and bioengineering 108(5): 1056-1067.

87. Drugmand JC, Schneider YJ, Agathos SN (2012) Insect cells as factories for biomanufacturing. Biotechnology advances 30(5): 1140-1157.

88. Jarvis DL (2003) Developing baculovirus-insect cell expression systems for humanized recombinant glycoprotein production. Virology 310(1): 1-7.

89. Caron AW, Archambault J, Massie B (1990) High-level recombinant protein production in bioreactors using the baculovirus–insect cell expression system. Biotechnology and bioengineering 36(11): 1133-1140.

90. Murhammer DW (2007) Baculovirus and insect cell expression protocols. Springer 388.

91. Hu YC, Yao K, Wu TY (2008) Baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert review of vaccines 7(3): 363-371.

92. Schaly S, Ghebretatios M, Prakash S (2021) Baculoviruses in gene therapy and personalized medicine. Biologics: Targets and Therapy 115-132.

93. Tani H (2008) Baculovirus vector for gene delivery and vaccine development.

94. Hu YC (2006) Baculovirus vectors for gene therapy. Advances in virus research 68: 287-320.

95. Fabre ML (2020) Baculovirus-derived vectors for immunization and therapeutic applications, in Emerging and reemerging viral pathogens. pp: 197-224.

96. Van Oers MM (20060 Vaccines for viral and parasitic diseases produced with baculovirus vectors. Advances in virus research 68: 193-253.

97. Trombetta CM, Marchi S, Montomoli E (2022) The baculovirus expression vector system: A modern technology for the future of influenza vaccine manufacturing. Expert Review of Vaccines 21(9): 1233-1242.

98. Neuhold J, Radakovics K, Lehner A, Weissmann F, Garcia MQ, et al. (2020) GoldenBac: a simple, highly efficient, and widely applicable system for construction of multi-gene expression vectors for use with the baculovirus expression vector system. BMC biotechnology 20: 1-15.

99. Martínez-Solís M, Herrero S, Targovnik AM (2019) Engineering of the baculovirus expression system for optimized protein production. Appl Microbiol Biotechnol 103(1): 113-123.

100. Liu H (2022) Bacterial extracellular vesicles-based therapeutic strategies for bone and soft tissue tumors therapy. Theranostics 12(15): 6576.

101. Xiong S, Ji J, Ma X (2019) Comparative life cycle energy and GHG emission analysis for BEVs and PHEVs: A case study in China. Energies 12(5): 834.

102. Jacob A (2021) Homologous recombination offers advantages over transposition-based systems to generate recombinant baculovirus for adeno-associated viral vector production. Biotechnology Journal 16(1): 2000014.

103. Lemaitre RP (2019) FlexiBAC: a versatile, open-source baculovirus vector system for protein expression, secretion, and proteolytic processing. BMC biotechnology 19: 1-11.

104. Hong Q (20230 Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development. Vaccines 11(7): 1218.

105. Azali MA (2022) Application of Baculovirus Expression Vector system (BEV) for COVID-19 diagnostics and therapeutics: a review. Journal of Genetic Engineering and Biotechnology 20(1): 98.

106. Fragoso-Saavedra M, Vega-López MA (2020) Induction of mucosal immunity against pathogens by using recombinant baculoviral vectors: Mechanisms, advantages, and limitations. Journal of Leucocyte Biology 108(3): 835-850.

107. Hong M (2022) Genetic engineering of baculovirus-insect cell system to improve protein production. Frontiers in bioengineering and biotechnology 10: 994743.

108. Mishra V (2020) A comprehensive guide to the commercial baculovirus expression vector systems for recombinant protein production. Protein and Peptide Letters 27(6): 529-537.

109. Joshi PR (2021) Advancements in molecular design and bioprocessing of recombinant adeno-associated virus gene delivery vectors using the insect-cell baculovirus expression platform. Biotechnology Journal 16(4): 000021.

110. Cox MM (2021) Innovations in the insect cell expression system for industrial recombinant vaccine antigen production. Vaccines 9(12): 1504.

111. Tang Y (2020) Construction of gateway-compatible baculovirus expression vectors for high-throughput protein expression and in vivo microcrystal screening. Scientific reports 10(1): 13323.

112. Puente-Massaguer EM, Lecina, Gòdia F (2020) Application of advanced quantification techniques in nanoparticle-based vaccine development with the Sf9 cell baculovirus expression system. Vaccine 38(7): 1849-1859.

113. Grose CZ, Putman, Esposito D (2021) A review of alternative promoters for optimal recombinant protein expression in baculovirus-infected insect cells. Protein expression and purification 186: 105924.